Literature DB >> 26454322

Effectiveness of intravenous haemocoagulase on haemorrhage control in bi-maxillary orthognathic surgery-A prospective, randomised, controlled, double-blind study.

Vikram Shetty1, Ganapathy Sriram S2.   

Abstract

Haemocoagulase is a snake venom protein derivative that is known to possess haemostatic activity. It is reported to minimise blood loss in orthopaedic, otorhinolaryngologic, and abdominal surgeries. The use of intravenous haemocoagulase in orthognathic surgery is unknown and not yet reported. The purpose of this trial is to study the efficacy of haemocoagulase in haemorrhage control in orthognathic surgery. Forty-six consecutive patients scheduled to undergo bi-maxillary orthognathic surgery within the time period of the study were recruited and randomized. They received either the study drug or placebo. All patients underwent operation with hypotensive anaesthesia. Intraoperative blood loss, operating time, drop in haemoglobin and haematocrit were the variables analysed in the study. Haemocoagulase caused an 11% (52 ml) reduction in blood loss in the study group (p = 0.01). There was no adverse reaction in any of the patients.
Copyright © 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood loss; Haemocoagulase; Orthognathic surgery

Mesh:

Substances:

Year:  2015        PMID: 26454322     DOI: 10.1016/j.jcms.2015.08.032

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  2 in total

1.  Operative time, blood loss, hemoglobin drop, blood transfusion, and hospital stay in orthognathic surgery.

Authors:  Ra'ed Ghaleb Salma; Fahad Mohammed Al-Shammari; Bishi Abdullah Al-Garni; Mohammed Abdullah Al-Qarzaee
Journal:  Oral Maxillofac Surg       Date:  2017-05-02

Review 2.  Animal Venom for Medical Usage in Pharmacopuncture in Korean Medicine: Current Status and Clinical Implication.

Authors:  Soo-Hyun Sung; Ji-Won Kim; Ji-Eun Han; Byung-Cheul Shin; Jang-Kyung Park; Gihyun Lee
Journal:  Toxins (Basel)       Date:  2021-02-01       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.